Pharminent · Daily Brief
October 14, 2026
Regulatory & Approvals
Happy Health’s cuffless blood pressure ring wins FDA clearance
Happy Health received FDA clearance for a wearable ring that continuously measures blood pressure without a cuff or external calibration.
MedCity News →
Analysis finds pharma-funded group ties among FDA panel patient representatives
An analysis found that nearly 40 percent of FDA advisory committee meetings over a 20-year period included a patient or consumer representative with active ties to an advocacy group funded by pharmaceutical companies.
STAT →
Clinical Data
BioNTech’s mRNA immunotherapy misses first objective in head and neck cancer
An early data check showed BioNTech’s mRNA cancer immunotherapy did not delay tumor progression in HPV16-positive head and neck cancer. The company said it will wait for further data, including on survival, before deciding the program’s fate.
BioPharma Dive →$BNTX
Deals & Partnerships
Roche licenses Rona’s ALK7-targeting RNAi obesity drug in $1B pact
Roche and Rona Therapeutics entered a global license agreement worth about $1 billion for an ALK7-targeting RNAi therapy aimed at lowering visceral fat.
BioPharma Dive →$RHHBY
Pfizer and Enodia sign $500M Sec61 inhibitor research deal
Pfizer and Enodia Therapeutics announced a research collaboration and licensing agreement potentially worth more than $500 million to discover and develop Sec61 inhibitors.
Pharmaceutical Technology →$PFE
Charles River partners with Magellan Stem Cells on Zelestrocel
Charles River Laboratories has entered a collaboration with Australian biotechnology firm Magellan Stem Cells to advance development and clinical progress of Magellan’s regenerative medicine candidate Zelestrocel.
Pharmaceutical Technology →
Ofichem agrees to acquire US drug substance CDMO Kinentia
Dutch company Ofichem has agreed to acquire Kinentia Biosciences, a drug substance CDMO based in Rensselaer, New York, that supports early-stage development, preclinical programs and clinical development. The transaction has not yet closed.
PharmaFile →
Business & Finance
BlackRock to buy majority stake in Humana’s CenterWell clinics for $2.8B
BlackRock is acquiring a majority stake in Humana’s CenterWell Senior Primary Care clinics for $2.8 billion, replacing Welsh, Carson, Anderson & Stowe as the private equity sponsor.
STAT →
J&J raises 2026 guidance as Tremfya drives third-quarter immunology sales
Johnson & Johnson reported strong third-quarter results led by Tremfya’s immunology sales and raised its 2026 guidance, despite several products facing generic and biosimilar competition.
Pharmaceutical Technology →$JNJ
Velaris to go public through reverse merger with Alaunos
Paragon spinout Velaris is going public through a reverse merger with Alaunos, a deal backed by key investor Fairmount.
BioPharma Dive →
Cori Clinical raises $4M seed round for trial design AI platform
Cori Clinical raised $4 million in a seed round led by Breega, with participation from Enzo, Heartfelt, Together Ventures and Bynd, to expand its AI platform for clinical trial design and grow its team.
PharmaFile →
Arletta Pharma Solutions appoints Jeannette Jager-van Dijk as CEO
Netherlands-based clinical-stage biopharmaceutical company Arletta Pharma Solutions, which develops therapies for female sexual disorders, has appointed Jeannette Jager-van Dijk as chief executive officer. She has more than three decades of leadership experience in women’s health, vaccines and specialty pharmaceuticals.
PharmaFile →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.